Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert ...

Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...